Maze Therapeutics Inc. (NASDAQ:MAZE) shares are down on Wednesday following the announcement of topline data from the Phase 2 HORIZON trial of MZE829, an oral treatment for APOL1-mediated kidney disease.

• Maze Therapeutics stock is among today’s weakest performers. What’s behind MAZE decline?

AMKD is a type of kidney disease caused by variants (changes) in the APOL1 (apolipoprotein L1) gene.

The trial results showed a 35.6% mean reduction in urinary albumin-to-creatinine ratio (uACR) among broad AMKD patients treated with MZE829, with 50% of patients achieving a reduction of over 30%.

uACR measures albumin (a blood protein) and creatinine (a waste product) in a urine sample to assess kidney function. A healthy kidney prevents albumin from entering the urine; thus, a normal result is less than 30 mg/g.

Additionally, patients with focal segmental glomerulosclerosis (FSGS) experienced an impressive 61.8% mean reduction in uACR.

FSGS is a rare disease where scarring (sclerosis) develops in scattered, individual kidney filters (glomeruli), leading to proteinuria, nephrotic syndrome, and potential kidney failure.

In patients with AMKD without diabetes, treatment with MZE829 resulted in a clinically meaningful mean reduction in uACR of 48.6%. In patients with AMKD with diabetes, five patients were evaluable per protocol for efficacy, with two patients achieving at least a 30% reduction in uACR. MZE829 was well-tolerated across all doses evaluated

Based on these results, Maze Therapeutics plans to advance MZE829 to a pivotal program while continuing to enroll in HORIZON.

For this topline analysis, 15 patients were enrolled in the HORIZON study, and all were included in a safety and tolerability analysis. Twelve patients were evaluated for efficacy.

Maze reported a 2025 cash balance of $360 million that will fund the operations into 2028.

Maze Therapeutics Analyst Consensus & Recent Actions

The stock carries a Buy Rating with an average price target of $56.33. Recent analyst moves include:

  • HC Wainwright: Buy (Raises target to $110 on March 25)
  • Truist Securities: Initiated with Buy (Target $68 on March 18)
  • Wedbush: Outperform (Raises target to $58 on March 16)
  • Mizuho: Initiated with Outperform (Target $97 on March 10)

MAZE Stock Price Activity: Maze Therapeutics shares were down 31.17% at $33.72 at publication on Wednesday, according to Benzinga Pro data.

Image via Shutterstock